Class of 2026
For trailblazing research involving hereditary cancer genetics, including the discovery of BRCA2 mutations in Ashkenazi Jewish populations, which led to the first genome-wide association study linking BRCA2 modifiers to breast cancer risk, and for further characterizing recurrent PAX5, APC, BLM, and MSH2 gene mutations in leukemia, breast, colon, and other cancers, thereby shaping current approaches to inherited cancer risk stratification, prevention, and early detection.
*Full-length biography in development
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]